Trial Profile
A 52 week double blind randomized controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Atherosclerosis; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms RUBENS
- 24 Nov 2009 New source identified and integrated (Netherlands Trial Register; NTR307)
- 17 Dec 2008 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.
- 20 Feb 2006 New trial record.